Status:
COMPLETED
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
Lead Sponsor:
UCB Pharma
Conditions:
Carcinoma
Non-Squamous Non-Small-Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour effects (part 2), of CDP791 combined with carboplatin and paclitaxel.
Detailed Description
This is a two part study to investigate the safety and anti-tumour effects of standard chemotherapy, plus an investigational drug (CDP791), in patients with advanced non small cell lung cancer. In pa...
Eligibility Criteria
Inclusion
- Male and female subjects with Stage IIIb (with malignant pleural effusion or if no pleural effusion is present subjects who are not candidates for combined modality therapy), Stage IV, or recurrent non-squamous, non-small-cell lung carcinoma.
- The subject must be aged 18 years or above.
- The subject must have ECOG performance status of 0 or 1 and a life expectancy of at least three months.
- Subjects will have measurable disease.
- The subject must be able to understand the information provided to them and to give written informed consent.
- Female subjects must be either postmenopausal, surgically sterilized, or using a method of contraception judged reliable by the Investigator.
- Male subjects must be using a method of contraception judged reliable by the Investigator.
Exclusion
- Subjects with squamous cell lung carcinoma.
- Subjects with lung lesions located centrally in the chest that involve major blood vessels.
- Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix. Subjects with previous malignancies are eligible provided that they have been disease free for five years or more.
- Presence of additional major chronic disease such as hepatic or renal dysfunction, cardiac dysfunction, peripheral vascular disease, evidence of a myocardial infarction within six months of Screening visit, tuberculosis or epilepsy.
- Subjects known to be infected with hepatitis B or C virus or HIV 1 or 2.
- Any evidence of serious active infection (ie requiring an iv antibiotic or antiviral agent).
Key Trial Info
Start Date :
August 15 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 25 2009
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT00152477
Start Date
August 15 2005
End Date
June 25 2009
Last Update
April 12 2022
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Budapest, Hungary
2
Deszk, Hungary
3
Mátraháza, Hungary
4
Nyíregyháza, Hungary